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Summary
We investigated the effect on thrombin generation in plasma of
the pentasaccharide that represent the AT Ill/binding site in
heparin. This compound has no effect on the breakdown of
thrombin in plasma. It dose-dependently inhibits the formation of
thrombin in both the intrinsic and the extrinsic pathway. If
coagulation is triggered by the complete prothrombinase complex
(phospholipid - factor Vu - factor Xu) under conditions in which
the large majority of factor Xu is bound to the complex, the
inhibition of prothrombinase activity is only minor. If no fac-
tor Vu is present or if the prothrombinase activity is triggered by
adding complete tenase (PLFVIII'-FIX.) or incomplete tenase
(PL-FIX.) to the plasma the inhibition by pentasaccharide is of
the same magnitude as that in the intrinsic or extrinsic system.
We conclude that the pentasaccharide inhibits blood coagula-
tion by katalysing the inactivation of free factor Xu. In contrast to
classical heparin it does inhibit the peak of thrombin formation in
platelet rich plasma, probably because it is less subject to
inactivation by heparin binding proteins from platelets than
classical heparin is.
Introduction
From data obtained with purified factors IIu and Xu added to
whole plasma it has been well documented that, with decreasing
molecular mass, heparin species gradually loose their ability to act
as a catalyst for antithrombin III dependent thrombin inactivation
but maintain an activity in factorXu inactivation (1-5). The
synthetic pentasaccharide prepared by Choay et al. (6, 7) that
represents the AT III binding site of heparin carries this tendency
to an extreme in that it has no activity in the AT Ill-thrombin
interaction but has a persistent high anti-factor X. activity (7).
Recently we developed a method to study the generation of
prothrombinase activity in plasma triggered via the extrinsic and
intrinsic pathways (8). We observed that the influence of standard
unfractionated heparin on the inactivation of thrombin and
factor Xn generated endogenously in plasma differs considerably
from its action on purified factors added to plasma. The inactiva-
tion of endogenously generated factor X. active in prothrombin-
ase was shown to be not or hardly enhanced by unfractionated
heparin (9, 10).
It follows that the mode of action of any heparin on activated
clotting factors generated in plasma cannot be foreseen from
studies carried out on purified factors. This prompted us to
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investigate the mode of action of the synthetic pentasaccharide in
plasma with our methods.
In platelet rich plasma the action of a heparin is even less
predictable than in platelet poor plasma. At concentrations of up
to 0.4 U/ml unfractionated heparin will not or hardly decrease the
peak amount of thrombin formed; it will only retard the appear-
ance of the thrombin peak (9, 11). This lack of inhibition can be
attributed to neutralization of the heparin by platelet factor 4 that
is released from the platelets as soon as they are activated by
thrombin formed in the plasma. The increase of the lagtime of
thrombin formation is due to the fact that, in the presence of
heparin, inhibition occurs of the small amounts bf thrombin that
form during the lagphase and that are responsible for the
triggering of the platelets (9, 11). Again, it seemed worthwile to
investigate what the behaviour of pentasaccharide would be in
this setup.
Part of the results given in this article has been presented as a
plenary lecture at the XIth I.S.TH. Congress (Brussels, 1987) (9).
Materials and Methods
All chemicals were of the highest grade commercially available.
Reptilase was obtained from Laboratoires Stago (Asnidres. France).
the solution was prepared according to the instructions of the manufac-
turer.
Soybean trypsin inhibitor (batch No.43 F-800) was obtained from
Sigma (St. Louis, USA). A 10 mg/ml solution in buffer A was used.
Staphylocoagulase was prepared as described by Hendrix et al. (12) or
obtained from Laboratoires Stago (Asnidres, France) and prepared
according to the indications of the manufacturer.
Chromogenic substrate for thrombin was H.D-Phe-Pip-Arg-pNA
2 }{CI (52238) from KABI, Sweden.
The phospholipid vesicle preparation contained 20% phos-
phatidylserine and 80% phosphatidylcholine and was prepared according
to Rosing et al (13). Kaolin was "Kaolin l6ger" provided by B.L.B
Laboratoires du Bois de Boulogne (Puteaux, France) Thromboplastin
was prepared according to Owren and Aas (14).
Buffers: A - 0.05 M Tiis-HCl, 0.1 M NaCl pH 7 35, with 0.5%
ovalbumin (Sigma); B - Buffer A with 20 mM EDTA pH7.9.
The 4th International Standard Heparin was supplied by Dr. T, W
Barrowcliffe and Pentasaccharide by the Choay Institute (15). The mean
molecular weight of the heparin was given as 14,000 and its specific
activity was 7941J/mg. It is assumed to contain -30% of high affinity
material, so that I U represents approximately 1.5 pg of high affinity
heparin or 0.1 nMole The pentasaccharide has a M.W. of 1,714.
Blood from healthy donors was collected on 0.13 M trisodium citrate;
nine parts of blood to one part of citrate solution. A first and a second
centrifugation were performed at 900 x g, at 15" C for 15 min. A third
centrifugation was done at 4" C, for t hour at 23,000 x g. The platelet free
plasma thus obtained was stored at -80'C. It was checked that the
clotting factors and the antiproteases were in the normal range. This
plasma is referred to as (platelet free) normal plasma in the text.
Defibrinated plasma was obtained by mixing an aliquot of plasma with
1:50 volume of a reptilase solution, letting a clot form for 10 min at37" C
and keeping the clotted plasma at 0' C for 10 min. The fibrin formed was
discarded by centrifugation (10 min, 5,000 x C, 4" C) or by winding it on a
small plastic spatula. The concentrations of factors II, V VII, VIII, IX,
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X, XI, and XII did not significantly change by the reptilase treatment as
has been shown before (8).
Platelet rich plasma was obtained by centrifugation (200 x g, 15 min)
of freshly drawn citrated blood from a fasting donor. The platelet count
was adjusted to 3 0 x 10'/ml with homologous platelet poor plasma
(centrifuged for 15 min at 10,000 x g). Plastic tubes and pipettes were
used throughout so as to minimize contact activation
Human brain thromboplastin was prepared as described in Owren and
Aas (14). It was homogenized in a Potter Elvehjem homogeniser for
3 min, centrifugated at 2,000 x g for 15 min and stored at -20" C in
0 1 ml aliquots Before use it was thawed, diluted with 0.05 M Tris-HCl
pH7.35 containing 100 mM of CaC12, so as to obtain a clotting time of
90 sec when incubated with normal non defibrinated plasma under the
same conditions as used for the thrombin generation experiments. The
dilution required was 1:40 for the batch of thromboplastin used here and
between 1:30 and 1:50 with other batches. The diluted thromboplastin
was incubated at37" C for I hour and then kept at room temperature In
this way it remained stable for at least 4 hours. In an independent study
(16), we showed that at this concentration of thromboplastin, the
reinforcement loop via factor VII dependent activation of factor IX does
not play a significant role: prothrombinase activities in the absence and in
the presence of factor IX were similar
Purified proteins: Human o,thrombin was prepared according to
Pletcher et al. (17), active site titrated and used for establishing a standard
curve. Factors V, Vu and factor Xn were obtained as described by
Lindhout et al (18). Factor VIII was prepared according to Vehar and
Davie (19) with the modifications by van Dieijen et al. (20) Factor IX
was prepared according to Fujikawa et al. (21) and activated by
incubation with purified factor XI" (22).
The breakdown constants of endogenous thrombin and the thrombin
generation curves were obtained as described in Hemker et al. (8), k is the
overall breakdown constant, k2 is defined as the o2-macroglobulin
dependent breakdown constant and ki is the remaining part, i. e. largely
AT III dependent (8)
Experimental
The pentasaccharide at concentrations of up to 10 pg/ml had no
influence on the inactivation of endogenous thrombin in normal plasma
The inactivation constant k (: kr + k2) was 1.187 + 0.024 (n: 10) at
5 pg/ml pentasaccharide against 1..179 + 0.015 (n : 20) for control
plasma.
When k2, the reaction constant of thrombin and c2-macroglobulin was
determined it appeared that, like with standard heparin (10), it was not
influenced by the presence of pentasaccharide k, : 0 246 + 0.008 (n : 8,
S.E M )  compared to the contro l  kz:0.253 + 0.005 (n :  20 S.E.M )
In Figs.-l- and 2 the influence of pentasaccharide on thrombin
generation in plasma is shown. There is an evident, dose dependent
inhibition, both in the intrinsic and extrinsic systems. Because thrombin
decay is not influenced by the pentasaccharide this inhibition cannot be
attributed to thrombin scavenging but must be attributed to the inhibition
of prothrombinase or to a decreased prothrombinase generation. Either
factor X^ is scavenged or its formation is inhibited
In the course of these experirnents it appeared that pentasaccharide is
adsorbed by kaolin. Therefore the usual concentration of kaolin (0.25 mgl
ml) used for triggering the intrinsic system was decreased tenfold. With
this amount of kaolin, contact activation appeared to be triggered to the
same extend as with the higher concentration but pentasaccharide
adsorption is hardly apparent anymore.
From Fig 3 it appears that there is only a minor degree of inhibition
when thrombin formation is triggered by a mixture of factors Xu and Vu
and phospholipid in concentrations that ensure that the large majority of
factor Xu molecules is bound in prothrombinase complex. If thrombin
formation is triggered by factor Xu and phospholipid alone the inhibition
is much more outspoken. At intermediate factor Va concentrations the
inhibition appeared to be dependent upon the amount of factor Vo
present (results not shown) In Fig.4 it is seen that the inhibition exerted
by pentasaccharide persists when thrombin fbrmation is triggered by the
complete factor X activating complex or by factor IXo and phospholipid
but without factor VIII.. If thrombin formation is triggered by factor IXn
and phospholipid there is an appreciable lagtime that is dose dependently
prolonged by pentasaccharide.
t ime (min)
Fig I The influence of pentasaccharide on thrombin generation in the
extrinsic system. Reaction mixture: normal plasma 240 pl, buffer A
containing heparin 60 pl, thromboplastin diluted 1:40 in CaCl2 0.1- M:
60 pl. A. Control. B. 0 05 pg/ml pentasaccharide C. 0.1 pg/ml pentasac-
charide. D. 0.3 pg/ml pentasaccharide E. 0.6 pg/ml pentasaccharide
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I tg ) I hc influence of pentasaccharide on thrombin generation in the
intrinsic system. Reaction mixture: normal plasma 240 pl, buffer A
containing: heparin, koalin (0 025 mg/ml) and phospholipid (1 pM) 60 pl,
CaCl2 0 1 M: 60 pl. A. Control. B. 0.05 pglmt pentasaccharide C 0 1 pglml
pentasaccharide. D. 0 3 pg/ml pentasaccharide E. 0.6 pglml pentasac-
charide
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Frg.3 The influence ofpentasaccharide on thrombin formation triggered
with complete and incomplete prothrombinase. Reaction mixture: 240 pl
plasma, 30 pl buffer A with or without pentasaccharide, 30 pl prothrom-
binase, 60 pl 0.1 M CaCl2. Complete prothrombinase: 5 mM CaCl2,
0 1 nM factor Xu, 10 nM factor Vu, 1 pM phospholipid. Incomplete
prothrombinase: 5 mM CaCl2, 0.1 nM factor X., 1 pM phospholipid.
a------O complete prothrombinase; control. O-O complete prothrom-
binase; 1.2 pglml pentasaccharide. a- - - -a incomplete prothrombin-
ase; control. O- - - -O incomplete prothrombinase; l-2 1tglml pentasac-
charide
Table I IC56 values for the inhibition of prothrombinase generation by
pentasaccharide and heparin in platelet free plasma
Pentasaccharide Heparin
pglml pglml U/ml
Intrinsic system
Extrinsic system
Complete prothrombinase
Factor Xn-phospholipid
Complete tenase
Factor IXn-phospholipid
0 .1
0 .1
>1 .5
0.2
0.2
0.2
0.15  0 .10
>0.15  >0.10
>0.15  >0 10
0.I2 0.08
0 15  0 .10
<0.008 <0.005
=
.= 100
.o
E
o
In Thble 1 we summarized the effects of pentasaccharide in terms of
the concentrations that would cause 50% inhibition of the peak of
prothrombinase activity in normal plasma Because pentasaccharide does
not influence thrombin breakdown its effect on prothrombinase can be
read directly from its effect on thrombin generatiron In Thble 1 the IC56
values of the inhibition of prothrombinase generation by heparin,
obtained from the data in Bdguin et at (10), are added for comparison.
The latter data are computed from thrombin generation curves and the
corresponding breakdown constants.
Next we determined the effect of the pentasaccharide in platelet rich
plasma. Here important differences with unfractionated hepirin become
apparent. Unfractionated heparin will retard the burst of thrombin
formation but will not influence the peak amount of thrombin formed.
The reason being that platelets, activated by trace amounts of thrombin
generated during the lagtime simultaneously make available procoagulant
phospholipids and heparin neutralizing platelet factor 4. Once the
platelets are activated thrombin activation is explosively enhanced by the
phospholipids that appear but also the heparin is virtually removed from
the system (9, 11).
Pentasaccharide does prolong the lagtime, as is to be expected because
it diminishes the amount of thrombin available for triggering the platelets
Contrary to unfractionated heparin it also markedly inhibits the peak of
thrombin format ion (Fig.  5) .
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Fig.4 The influence of pentasaccharide on thrombin generation trig-
gered with complete and incomplete tenase complex. Reaction mixture:
240 1tl plasma, 30 pl buffer A with or without pentasaccharide 30 pl
tenase, 60 pl 0 1 M CaCl2. Complete tenase: 5 mM CaCl2, 10 nM factor
IX", 5 U/ml factor VIII, 2 nM factor IIu, 1 pM phospholipid. Incomplerc
tenase: 5 mM CaCl2, 10 nM factor Dt , 1 pM phospholipid. A. Controlr
complete tenase. B. Complete tenase; 0.200 pglml pentasaccharide. D.
Control; incomplete tenase. E Incomplete tenase; 0.050 pg/ml pentasac-
charide. F, Incomplete tenase; 0.200 lrglml pentasaccharide
t ime  (m in )
Flg 5 Influence of pentasaccharide on the thrombin generation in pRp.
Reaction mixture: Platelet rich plasma: 240 pl; pentasaccharide or buffer
A: 60 pl; thromboplastin 1:400 in CaCl2 100 mM: 60 pl. a-a control,
 
- - - - 
 
pentasaccharide 1.2 pglml
399
Discussion
We wanted to investigate the influence of pentasaccharide on
the generation and the disappearance of thrombin in plasma,
under conditions as near as possible to the in vivo situation.
In previous articles we showed that standard heparin causes a
clearcut, dose dependent, increase of the pseudo first-order
reaction constant of thrombin decay but does not or hardly inhibit
prothrombinase at concentrations that inhibit thrombin genera-
tion for over 85% (9, 10). Pentasaccharide does not influence the
inactivation of thrombin by AT III. It still does inhibit the
formation of thrombin in plasma though (Figs. 1 and 2). There-
fore it must act at a higher level in the coagulation cascade, either
by increasing factor Xo inactivation or by inhibiting factor X
activation or both.
From Fig.3 we see that prothrombinase triggered thrombin
formation is inhibited only slightly if an excess of factor Vu is
present but markedly in the absence of factor V". This indicates
that free factor Xu rather than factor Xu bound in the complete
prothrombinase complex is the species attacked by the AT III-
pentasaccharide complex.
From Fig.4 it is seen that the thrombin generation provoked by
complete tenase is inhibited significantly more than that caused by
complete prothrombinase. Apart from the effect on the lagphase
the inhibition of thrombin formation triggered by factor IXu-
phospholipid and by complete tenase (factors IXu and VIII. and
phospholipid) are comparable (Fig.4, Table 1). This indicates
that factor IXu needs not be protected by factor VIII" probably
because factor IXu is not subject to important AT Ill-pentasac-
charide induced inactivation.
The fact that thrombin generation induced by complete or
incornplete tenase and incomplete prothrombinase is markedly
inhibited whereas that induced by complete prothrombinase is
not, indicates that the product of tenase, i. e. factor Xu, goes
through a free stage and is not immediately bound to factor Vu
and phospholipid, after its production. It also is in agreement with
the observation of Barrowcliffe that pentasaccharide will hardly
exert an inhibitory action on factor Xu bound in prothrombinase
(23).
This might seem to be in contradiction with our previous
proposiiions on the mode of action of unfractionated heparin (9,
10). There we concluded that heparin hardly inhibits prothrom-
binase at concentrations that almost completely extinguish free
thrombin formation. We explained this by assuming that factor Xu
is protected by phospholipid and factor Vu which implies that the
inhibition of free factor Xu plays a negligible role. It may well be
that still higher concentrations of heparin will inhibit prothrom-
binase by their action on factor Xu. In plasma this cannot be
demonstrated with our methods, because we need sufficient
thrombin levels in order to be able to calculate the course of
prothrombinase. Pentasaccharide allows this effect to be observed
because it does not influence thrombin breakdown.
If at high concentration (e.g. >0.1 U/ml) heparin inhibits
prothrombinase, this action cannot significantly contribute to the
anticoagulant effect because at these levels the antithrombin
action prevents the existence of anything but traces of thrombin.
The prolongation of the lag phase of thrombin formation in the
intrinsic system (Fig.2) finds an unforced explanation in the fact
that low ambient concentrations of thrombin during the lagphase
will retard feedback activation of factor VIII. This explanation is
the same as that forwarded for the prolongation of the lagphase
by heparin (10), be it that the cause of the low thrombin levels
during the lagtime in the case of pentasaccharide is low prothrom-
bin activation whereas with heparin it is increased thrombin
breakdown.
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Heparin will inhibit intrinsic prothrombin activation to a
greater extent than the extrinsic one. This is attributed to the fact
that factor IXu, in the absence of factor VIII', i. e. during the 1ag
time, is subject to heparin-AT III dependent decay (9, 10).
Pentasaccharide shows approximately the same inhibition in the
intrinsic and in the extrinsic system (Table 1), again indicating
that contrary to heparin, pentasaccharide does not significantly
enhance the inactivation of factor IXu in plasma. This is corrobo-
rated by the observation that it is possible to provoke notable
thrombin formation by factor IX.-phospholipid in the absence of
factor VIII., whereas with heparin this is impossible (Fig.4,
ref. 10).
It has been shown that trace amounts of thromboplastin
provoke the generation of traces of thrombin that witl activate
platelets in platelet rich plasma. The time necessary for this
process is the lagtime of platelet activation. Once the platelets are
activated they will make phospholipid and factor V available and
explosive thrombin formation ensues. During the lagtime the
system may be conceived as inactive platelets suspended in
platelet poor plasma (9, 11).
Pentasaccharide, like classical heparin, will restrict the availa-
bility of trace amounts of thrombin during the lagphase, not by
thrombin scavenging but by inhibition of prothrombinase forma-
tion. The prolongating effect on the lagtime is the same however.
Unlike unfractionated heparin, of which up to 0.4 Ulml
(- 2.I pglml) are completely neutralized by activated platelets
(9, 11), pentasaccharide appears to maintain part of its activity in
the presence of activated platelets because it does inhibit throm-
bin generation in platelet rich plasma, be it less than in platelet
free plasma (Fig. 1, 2 and 5). The explanation of this phenomenon
is either that the affinity of neutralizing protein from platelets is
less for pentasaccharide than for heparin or that the higher molar
concentration of t.2 pglml of pentasaccharide (- 0.7 pM) com-
pared to that of 0 4 U/ml of heparin (- 0.15 pM) represents a
molar excess that exceeds the neutralizing capacity of the released
proteins.
It appears that in order to appreciate the differences between
unfractionated heparin and low molecular weight heparins it is
not sufficient to study the effects in platelet free plasma only,
because also the susceptibility to neutralization by platelet
p roduc ts  w i l l  p lay  a  ro le  in  v ivo .
As long as the therapeutic action of heparin has not been
demonstrated to be dissociable from its action on coagulation, the
net amount of thrombin observed in clotting platelet rich plasma
is probably the best guide for judging its effective concentration,
and this for two reasons: a) Decrease of thrombin availability is
the common denominator of every effective type of
pharmacological antithrombotic therapy known until this
moment. b) Thrombin inhibition in platelet rich plasma comes
nearer to the situation in vivo than thrombin inhibition in artificial
systems.
Pentasaccharide represents a type of heparin that is fundamen-
tally different from unfractionated heparin, in that it acts on free
factor Xu and not on thrombin decay. The final effect in plasma is
the same: less free thrombin is available. It therefore is not
surprising that pentasaccharide has been shown to possess anti-
thrombotic action in animal experiments (24).
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